- Home
- SRL vs KYTX Comparison
SRL vs KYTX Comparison
Compare SRL & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRL
- KYTX
- Stock Information
- Founded
- SRL 2017
- KYTX 2018
- Country
- SRL China
- KYTX United States
- Employees
- SRL N/A
- KYTX N/A
- Industry
- SRL Professional Services
- KYTX
- Sector
- SRL Consumer Discretionary
- KYTX
- Exchange
- SRL Nasdaq
- KYTX NYSE
- Market Cap
- SRL 115.0M
- KYTX 125.2M
- IPO Year
- SRL N/A
- KYTX 2024
- Fundamental
- Price
- SRL $8.29
- KYTX $2.15
- Analyst Decision
- SRL
- KYTX Buy
- Analyst Count
- SRL 0
- KYTX 5
- Target Price
- SRL N/A
- KYTX $19.20
- AVG Volume (30 Days)
- SRL 4.1K
- KYTX 311.8K
- Earning Date
- SRL 04-28-2025
- KYTX 05-13-2025
- Dividend Yield
- SRL 3.18%
- KYTX N/A
- EPS Growth
- SRL N/A
- KYTX N/A
- EPS
- SRL N/A
- KYTX N/A
- Revenue
- SRL $33,997,735.00
- KYTX N/A
- Revenue This Year
- SRL N/A
- KYTX N/A
- Revenue Next Year
- SRL N/A
- KYTX N/A
- P/E Ratio
- SRL N/A
- KYTX N/A
- Revenue Growth
- SRL N/A
- KYTX N/A
- 52 Week Low
- SRL $5.74
- KYTX $1.88
- 52 Week High
- SRL $9.99
- KYTX $24.91
- Technical
- Relative Strength Index (RSI)
- SRL 60.99
- KYTX 38.60
- Support Level
- SRL $8.00
- KYTX $1.88
- Resistance Level
- SRL $8.11
- KYTX $2.57
- Average True Range (ATR)
- SRL 0.20
- KYTX 0.20
- MACD
- SRL 0.03
- KYTX -0.01
- Stochastic Oscillator
- SRL 100.00
- KYTX 35.06
About SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.